Brief: Arcutis Biotherapeutics Inc Continues To Evaluate And Explore Opportunities For Further Efficiencies And Cost Savings
19/10/2023 21:11
Oct 19 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS BIOTHERAPEUTICS INC: CONTINUES TO EVALUATE AND
EXPLORE
OPPORTUNITIES FOR FURTHER EFFICIENCIES AND COST SAVINGS
* ARCUTIS BIOTHERAPEUTICS- DUING QUARTER IMPLEMENTED STEPS
TO
DRIVE EFFICIENCIES AND ENHANCE ITS FINANCIAL FLEXIBILITY,
INCLUDING HEADCOUNT REDUCTIONS
* ARCUTIS BIOTHERAPEUTICS INC: SEES PRELIMINARY TOTAL
REVENUES OF
ABOUT$38.1 MILLION FOR QUARTER ENDED SEPTEMBER 30, 2023
* ARCUTIS BIOTHERAPEUTICS - EXPECTS TO REPORT ABOUT $228.1
MILLION
OF CASH, CASH EQUIVALENTS, RESTRICTED CASH AND MARKETABLE
SECURITIES AS OF SEPTEMBER 30
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf